Actively Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Led by MediLink Therapeutics (Suzhou) Co., Ltd. · Updated on 2026-01-14
220
Participants Needed
19
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
CONDITIONS
Official Title
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Informed consent signed before study start
- Willingness and ability to comply with study visits and procedures
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Pathologically confirmed diagnosis of advanced solid tumor for Parts 1 and 2
- Histologically or cytologically confirmed locally advanced unresectable or metastatic disease for Part 3
- Adequate organ and bone marrow function
- At least one extracranial measurable tumor lesion
- Adequate archival formalin-fixed paraffin embedded (FFPE) tissue from prior biopsy
You will not qualify if you...
- Prior treatment with an agent targeting CDH17
- Previous discontinuation of a topoisomerase I inhibitor due to treatment-related toxicities
- Prior treatment with an antibody-drug conjugate containing a topoisomerase I inhibitor
- Concurrent enrollment in another clinical study except observational studies
- Insufficient washout period from prior anticancer therapy before first study drug dose
- Major surgery within 4 weeks before first study drug dose or planned major surgery during study
- Use of long-term systemic steroids or immunosuppressive therapy within 2 weeks before first study drug dose
- Receipt of any live vaccine within 4 weeks before first study drug dose or planned receipt during study
- Diagnosis or signs of spinal cord compression or leptomeningeal carcinomatosis
- Uncontrolled or significant cardiovascular or cerebrovascular disease
- History of non-infectious interstitial lung disease (ILD)/pneumonitis requiring steroids or active ILD/pneumonitis
- Severe pulmonary compromise from other lung illnesses
- Uncontrolled third-space fluid requiring repeated drainage
- Digestive diseases causing bleeding, perforation, jaundice, or obstruction
- Active tuberculosis based on medical history
- Known HIV infection
- Active hepatitis C infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
Mayo Clinic Arizona
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California, United States, 90404
Actively Recruiting
3
Yale Cancer Center
New Haven, Connecticut, United States, 06519
Actively Recruiting
4
The University of Kansas Cancer Center (KUCC)
Kansas City, Kansas, United States, 66205
Actively Recruiting
5
University of Maryland Medical Center-Greenebaum Cancer Ctr - Medical Oncology
Baltimore, Maryland, United States, 21201
Not Yet Recruiting
6
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Actively Recruiting
7
Columbia University Irving Medical Center
New York, New York, United States, 10032
Actively Recruiting
8
Duke University Medical Center (DUMC)
Durham, North Carolina, United States, 27710
Actively Recruiting
9
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45219
Actively Recruiting
10
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, United States, 44195
Actively Recruiting
11
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
12
UT Health San Antonio - Mays Cancer Center
San Antonio, Texas, United States, 78229
Actively Recruiting
13
University of Wisconsin Health - UW Carbone Cancer Center
Madison, Wisconsin, United States, 53792
Not Yet Recruiting
14
Peking Union Medical College Hospital
Beijing, Bejing, China, 100730
Actively Recruiting
15
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150081
Not Yet Recruiting
16
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China, 250117
Not Yet Recruiting
17
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
18
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
19
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Not Yet Recruiting
Research Team
A
Angie Cao, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here